Jump to content
Content on WikiMesothelioma is reviewed by three named attorneys at Danziger & De Llano LLP prior to publication. See our editorial standards.

Pleural vs Peritoneal Mesothelioma

From WikiMesothelioma — Mesothelioma Knowledge Base


Pleural vs. Peritoneal Mesothelioma
Feature Pleural Peritoneal
Location Lung lining Abdominal lining
Share of cases ~80–90% ~10–20%
US cases/year ~2,500+ ~600–800
Median age ~73 ~62
Male share ~77% ~53%
Lead symptom Shortness of breath Abdominal swelling
Curative surgery P/D or EPP CRS/HIPEC
Median survival ~12–18 months ~53 months (CRS/HIPEC)
5-year survival ~5–12% ~41–59% (selected)

Executive Summary

Pleural and peritoneal mesothelioma are two forms of the same asbestos-caused cancer that differ profoundly in where they start, how they present, and — most importantly — how long patients survive. Pleural mesothelioma arises in the lining of the lungs (the pleura) and accounts for roughly 80–90% of all mesothelioma diagnoses, while peritoneal mesothelioma arises in the lining of the abdomen (the peritoneum) and accounts for approximately 10–20%.[1][2] Both are traced to the inhalation or ingestion of asbestos fibers, typically 20 to 50 years before diagnosis.[3]

The single most consequential difference is prognosis. A population-based SEER analysis of 9,701 pleural mesothelioma patients reported 1-year survival of 33% and 5-year survival of just 5%.[4] By contrast, a 405-patient multi-institutional registry found that peritoneal mesothelioma treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) achieved a median overall survival of 53 months and 5-year survival of 47%.[5] This gap is driven by biology and access to surgery: the peritoneal cavity is a contained space where a surgeon can physically remove visible tumor and bathe the abdomen in heated chemotherapy, an option rarely available in the chest.[6]

The two diseases also differ in who they affect and how they announce themselves. Pleural mesothelioma skews older (median age ~73) and heavily male (~77%), presenting with shortness of breath, chest pain, and fluid around the lung.[4] Peritoneal mesothelioma strikes younger patients (median age ~62), affects women nearly as often as men, and presents with abdominal swelling, ascites, and unexplained weight loss.[7] Despite these differences, patients diagnosed with either type retain identical legal rights to asbestos trust fund claims and lawsuit compensation.[8]

At-a-Glance

Pleural vs. peritoneal mesothelioma at a glance:

  • Peritoneal mesothelioma survives roughly 4x longer than pleural when optimally treated — median 53 months with CRS/HIPEC versus 12–18 months for pleural disease[5][9]
  • Pleural mesothelioma is 4–8x more common — it makes up ~80–90% of the roughly 3,000 US mesothelioma cases each year, while peritoneal makes up ~10–20%[1][2]
  • Location determines everything — pleural disease grows in the lung lining and causes breathing problems; peritoneal disease grows in the abdominal lining and causes swelling and digestive symptoms[10][11]
  • Peritoneal patients are younger and more often female — median age ~62 with a near-equal sex ratio, versus median age ~73 and ~77% male for pleural disease[4][7]
  • Surgery is fundamentally different — pleural mesothelioma uses pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP); peritoneal mesothelioma uses cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC)[6][5]
  • Pleural mesothelioma has an FDA-approved first-line immunotherapy — nivolumab plus ipilimumab extended median survival to 18.1 months versus 14.1 months for chemotherapy in the CheckMate 743 trial[9]
  • Peritoneal survival is stage-dependent and measurable — 5-year survival by stage runs 87% (Stage I), 53% (Stage II), and 29% (Stage III) in the peritoneal TNM registry[12]
  • Both share the same cause and latency — asbestos exposure 20–50 years earlier, though peritoneal cases more often trace to take-home or secondary exposure[3]
  • Epithelioid cell type predicts better outcomes in both — and peritoneal mesothelioma is disproportionately epithelioid (~79%), part of why it responds better to aggressive surgery[5]
  • Compensation rights are identical — trust fund claims, settlements, and VA benefits are available for both types regardless of the lower asbestos-attribution rate in peritoneal disease[8][13]

Key Facts

Measure Pleural Mesothelioma Peritoneal Mesothelioma
Primary site Pleura (lung lining) Peritoneum (abdominal lining)
Share of all mesothelioma ~80–90%[1] ~10–20%[2]
Median age at diagnosis ~73 years[4] ~62 years[7]
Male predominance ~77% male[4] ~53% male[7]
Cardinal symptom Dyspnea, pleural effusion, chest pain[10] Abdominal distension, ascites, weight loss[11]
Curative-intent surgery P/D (preferred) or EPP[6] CRS + HIPEC[5]
First-line systemic therapy Nivolumab + ipilimumab or platinum/pemetrexed[9] Platinum/pemetrexed; immunotherapy extrapolated[6]
Median overall survival ~12–18 months[9] ~53 months with CRS/HIPEC[5]
5-year survival ~5% (SEER); ~5–12% overall[4] ~41–59% in selected patients[5]
Predominant cell type Epithelioid, sarcomatoid, biphasic ~79% epithelioid[5]
Typical latency 20–50 years[3] 20–50 years[3]
Compensation eligibility Trust funds, lawsuits, VA benefits[8] Trust funds, lawsuits, VA benefits[8]

What Is the Difference Between Pleural and Peritoneal Mesothelioma?

The fundamental difference between pleural and peritoneal mesothelioma is anatomical: they arise in different mesothelial membranes within the body. Mesothelium is the thin, protective tissue that lines the body's internal cavities and coats its organs. When asbestos fibers lodge in this tissue and trigger malignant transformation decades later, the resulting cancer is named for the specific membrane it invades.[1]

Pleural mesothelioma develops in the pleura — the double-layered membrane surrounding each lung and lining the inside of the chest wall. Because inhaled asbestos fibers travel directly into the lungs and migrate to the pleural surface, this is by far the most common site, representing roughly 80–90% of all mesothelioma diagnoses.[10][2] As the tumor grows, it thickens the pleura, traps fluid (pleural effusion), and progressively restricts the lung's ability to expand.

Peritoneal mesothelioma develops in the peritoneum — the membrane lining the abdominal cavity and enveloping the stomach, intestines, liver, and other organs. Fibers are thought to reach the peritoneum through the lymphatic system or by being coughed up and swallowed, eventually lodging in the abdominal lining.[11][3] Peritoneal disease accounts for approximately 10–20% of cases and, unlike pleural disease, affects a younger and more sex-balanced population.[7]

Two rarer forms exist for completeness: pericardial mesothelioma (in the lining around the heart) and testicular mesothelioma (in the tunica vaginalis), which together account for well under 1% of diagnoses. This page focuses on the two dominant forms.[1]

How Do Symptoms Differ Between Pleural and Peritoneal Mesothelioma?

Because the two cancers grow in different body cavities, their early warning signs are almost entirely distinct — a difference that frequently affects how quickly a correct diagnosis is reached.

Pleural mesothelioma produces respiratory and chest symptoms. The most common presenting complaint is shortness of breath (dyspnea), caused by fluid accumulating between the pleural layers and by the stiffening of the lung lining. Patients also report persistent dry cough, chest wall pain, difficulty swallowing, fatigue, and unexplained weight loss.[10] Because these symptoms mimic pneumonia, chronic obstructive pulmonary disease, and other common conditions, pleural mesothelioma is often misdiagnosed for months.[7]

Peritoneal mesothelioma produces abdominal and digestive symptoms. The dominant feature is abdominal distension from ascites — fluid buildup in the abdominal cavity that occurs in roughly three-quarters of patients. Other signs include abdominal pain, bloating, changes in bowel habits, nausea, loss of appetite, and weight loss.[11][7] These symptoms are easily attributed to irritable bowel syndrome, hernias, or ordinary digestive complaints, which is a leading reason peritoneal mesothelioma is frequently diagnosed at an advanced stage.

A practical consequence follows from this symptom divergence: a patient with an asbestos-exposure history who develops unexplained breathing problems should be evaluated for pleural disease, while one who develops unexplained abdominal swelling should be evaluated for peritoneal disease. In both cases, disclosing the asbestos history to the physician is critical, because it dramatically raises the index of suspicion for mesothelioma.[14]

How Are Pleural and Peritoneal Mesothelioma Diagnosed?

Both types follow a similar diagnostic pathway — imaging, fluid or tissue sampling, and confirmatory pathology — but the specific tests differ by location.

For pleural mesothelioma, diagnosis typically begins with a chest X-ray and CT scan revealing pleural thickening and effusion, followed by thoracentesis (draining and analyzing pleural fluid) and, ultimately, a thoracoscopic biopsy for definitive tissue diagnosis.[14] For peritoneal mesothelioma, diagnosis usually starts with abdominal CT or MRI showing ascites and peritoneal thickening, followed by paracentesis (draining abdominal fluid) and laparoscopic biopsy.[11]

In both diseases, the pathologist determines the cell type — epithelioid, sarcomatoid, or biphasic — which is one of the strongest predictors of prognosis. Epithelioid tumors respond far better to treatment than sarcomatoid tumors. Peritoneal mesothelioma is disproportionately epithelioid (roughly 79% in surgical series), which is one biological reason it responds better to aggressive therapy.[5] Immunohistochemical staining (for markers such as calretinin and WT-1) confirms the mesothelial origin and distinguishes mesothelioma from lung or ovarian cancers that can appear similar.[14]

An accurate, documented diagnosis is also the foundation of any legal claim. The pathology report identifying mesothelioma and its cell type becomes a central piece of evidence when pursuing asbestos trust fund claims or litigation.[15]

How Does Treatment Differ Between the Two Types?

Treatment is where the two diseases diverge most dramatically, and the difference explains much of the survival gap.

For pleural mesothelioma, the standard curative-intent surgeries are pleurectomy/decortication (P/D), which strips the diseased pleura while sparing the lung, and extrapleural pneumonectomy (EPP), a more radical operation that removes the lung, pleura, part of the diaphragm, and the pericardium. P/D is increasingly preferred because it carries lower mortality with comparable survival.[6] On the systemic side, pleural mesothelioma now has an FDA-approved first-line immunotherapy: the combination of nivolumab plus ipilimumab, which in the phase 3 CheckMate 743 trial extended median overall survival to 18.1 months versus 14.1 months for platinum/pemetrexed chemotherapy.[9]

For peritoneal mesothelioma, the transformative treatment is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). The surgeon removes all visible tumor from the abdominal cavity (cytoreduction), then circulates heated chemotherapy directly through the abdomen to destroy microscopic residual disease.[5] This is feasible in the peritoneum precisely because it is a contained space — an approach that has no direct equivalent in the chest. The multi-institutional registry establishing this approach reported that patients achieving complete or near-complete cytoreduction plus HIPEC lived far longer than those treated with chemotherapy alone.[5]

The eligibility gate for peritoneal surgery is the Peritoneal Cancer Index (PCI), which scores tumor spread across 13 abdominal regions from 0 to 39. Lower PCI predicts both surgical resectability and survival, which is why early referral to a specialized peritoneal surface malignancy program is so important.[12] A patient told "there is nothing that can be done" for peritoneal mesothelioma should seek a second opinion at a high-volume CRS/HIPEC center before accepting that conclusion.[6]

How Do Survival and Prognosis Compare?

The survival difference between the two diseases is among the largest in oncology for cancers that share a single cause.

For pleural mesothelioma, the population-based SEER analysis of 9,701 patients diagnosed between 1973 and 2006 reported 6-month, 1-year, and 5-year overall survival of 55%, 33%, and 5%, respectively.[4] Modern immunotherapy has improved these figures — CheckMate 743 reported a 2-year survival rate of 41% with nivolumab plus ipilimumab — but pleural mesothelioma remains a disease measured in months to a few years for most patients.[9]

For peritoneal mesothelioma, the picture is substantially more hopeful in patients eligible for surgery. The landmark 405-patient CRS/HIPEC registry reported median overall survival of 53 months with 3- and 5-year survival of 60% and 47%.[5] Survival is strongly stage-dependent: the peritoneal TNM staging study found 5-year survival of 87%, 53%, and 29% for Stage I, II, and III disease.[12] Even accounting for the fact that only surgically eligible patients achieve these outcomes, peritoneal mesothelioma is unambiguously the most treatable mesothelioma location.[16]

Four prognostic factors independently improved survival in the peritoneal registry: epithelioid cell type, absence of lymph node metastasis, complete or near-complete cytoreduction, and receipt of HIPEC.[5] For both diseases, the two universal levers on prognosis are cell type (epithelioid favorable) and access to aggressive, specialized treatment delivered as early as possible after diagnosis.

Why Does Peritoneal Mesothelioma Have a Better Prognosis?

Three interlocking factors explain why peritoneal mesothelioma outlives pleural mesothelioma when both are optimally treated.

First, anatomy favors surgery. The peritoneal cavity is a bounded compartment in which a surgeon can physically remove visible tumor and then perfuse the entire space with heated chemotherapy. The chest cavity, by contrast, contains the constantly moving lungs and heart, making complete tumor removal and cavity-wide chemotherapy far harder to deliver safely.[5][6]

Second, tumor biology is more favorable. Peritoneal mesothelioma is disproportionately epithelioid — the cell type most responsive to treatment — and less often sarcomatoid, the most aggressive subtype. This biological skew works in patients' favor before treatment even begins.[5]

Third, patients are younger and healthier. With a median diagnosis age roughly a decade younger than pleural mesothelioma and a more sex-balanced population, peritoneal patients are more likely to tolerate the demanding CRS/HIPEC operation.[7] None of this makes peritoneal mesothelioma benign — untreated, it is as lethal as pleural disease — but it does mean that the difference between an ordinary oncology referral and a specialized peritoneal surface malignancy program can be measured in years of life.[16]

Do Both Types Qualify for the Same Compensation?

Yes. A diagnosis of either pleural or peritoneal mesothelioma establishes the same legal rights to compensation, because both are recognized asbestos-related cancers.[8] The lower rate of documented asbestos exposure in peritoneal cases does not bar recovery; experienced attorneys reconstruct exposure history through occupational records, product identification, and witness testimony.[17]

Compensation avenues identical for both types include asbestos bankruptcy trust fund claims (more than $30 billion set aside by bankrupt manufacturers), personal injury lawsuits against solvent defendants, and VA benefits for veterans exposed during military service.[18][13] Because every state imposes a statute of limitations — typically one to three years from the date of diagnosis — prompt legal consultation is important regardless of which type is diagnosed.[15]


⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Frequently Asked Questions

Which is more common, pleural or peritoneal mesothelioma?

Pleural mesothelioma is far more common, accounting for roughly 80–90% of all mesothelioma diagnoses, while peritoneal mesothelioma accounts for approximately 10–20%.[1][2]

Is peritoneal mesothelioma more survivable than pleural mesothelioma?

Yes, when it can be treated surgically. Peritoneal mesothelioma treated with CRS/HIPEC has reported median survival of about 53 months and 5-year survival of 41–59%, compared with roughly 5–12% 5-year survival for pleural mesothelioma.[5][4]

Can you have both pleural and peritoneal mesothelioma?

It is uncommon but possible for mesothelioma to involve more than one cavity. Peritoneal involvement has been documented in a subset of pleural mesothelioma cases, and vice versa, though most patients are diagnosed with disease confined to a single site.[1]

Do pleural and peritoneal mesothelioma have the same cause?

Both are caused by asbestos exposure, typically 20 to 50 years before diagnosis. Pleural disease is more strongly tied to direct occupational inhalation, while peritoneal cases more often trace to take-home or secondary exposure.[3]

What is CRS/HIPEC and why is it only used for peritoneal disease?

CRS/HIPEC is cytoreductive surgery to remove visible tumor followed by heated chemotherapy circulated through the abdomen. It is feasible in the peritoneum because it is a contained cavity; the chest cavity's anatomy makes an equivalent procedure impractical.[5][6]

Does the type of mesothelioma affect my compensation?

No. Both pleural and peritoneal mesothelioma qualify for asbestos trust fund claims, lawsuits, and VA benefits. The type of mesothelioma does not limit your legal rights.[8][13]

Quick Statistics

  • ~80–90% of mesothelioma cases are pleural; ~10–20% are peritoneal[1][2]
  • 53 months — median survival for peritoneal mesothelioma with CRS/HIPEC[5]
  • 5% — 5-year survival for pleural mesothelioma in the SEER population study[4]
  • 47% — 5-year survival for peritoneal mesothelioma with complete cytoreduction and HIPEC[5]
  • 18.1 vs. 14.1 months — median survival with nivolumab/ipilimumab versus chemotherapy in pleural disease[9]
  • 87% / 53% / 29% — 5-year peritoneal survival by TNM Stage I / II / III[12]
  • ~79% of peritoneal mesotheliomas are epithelioid, the most treatable cell type[5]
  • ~73 vs. ~62 — median age at diagnosis for pleural versus peritoneal disease[4][7]
  • 20–50 years — typical latency from asbestos exposure to diagnosis for both types[3]

Free, Confidential Case Evaluation

Call (855) 699-5441 or visit dandell.com/contact-us

No upfront fees • Experienced representation • National practice

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Types of Mesothelioma, Mesothelioma Lawyer Center.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Mesothelioma Cell Types, Mesothelioma.net.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 Asbestos Exposure, Mesothelioma.net.
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5(11):1841-8. PMID: 20975379.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 5.14 5.15 5.16 5.17 5.18 5.19 Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42. PMID: 19917862. doi:10.1200/JCO.2009.23.9640.
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 Mesothelioma Treatment, Mesothelioma Lawyer Center.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 Mesothelioma Symptoms, Mesothelioma.net.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 8.5 Mesothelioma Compensation, Danziger & De Llano.
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. PMID: 33485464.
  10. ↑ 10.0 10.1 10.2 10.3 Pleural Mesothelioma, Mesothelioma Lawyer Center.
  11. ↑ 11.0 11.1 11.2 11.3 11.4 Peritoneal Mesothelioma, Mesothelioma Lawyer Center.
  12. ↑ 12.0 12.1 12.2 12.3 Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117(9):1855-63. PMID: 21509762. doi:10.1002/cncr.25640.
  13. ↑ 13.0 13.1 13.2 Mesothelioma Settlements, Mesothelioma Attorney.
  14. ↑ 14.0 14.1 14.2 Mesothelioma Diagnosis, Mesothelioma.net.
  15. ↑ 15.0 15.1 Filing a Mesothelioma Claim, Danziger & De Llano.
  16. ↑ 16.0 16.1 Mesothelioma Prognosis, Mesothelioma Lawyer Center.
  17. ↑ The Mesothelioma Legal Process, Mesothelioma Attorney.
  18. ↑ Asbestos Trust Funds, Danziger & De Llano.
Retrieved from "https://wikimesothelioma.com/w/index.php?title=Pleural_vs_Peritoneal_Mesothelioma&oldid=3957"